Caribou Biosciences Halts CAR-T Programs and Explores Strategic Sale

Key Facts

Caribou Biosciences announced it is halting its CAR-T cell therapy programs. Investing.com reported that the company has initiated a formal process to explore strategic alternatives, which may include a potential sale or merger.

The decision follows a strategic review of the company's pipeline and capital allocation intended to maximize shareholder value within a challenging biotech environment. Caribou has hired advisors to oversee the exploration of these alternatives, including asset divestitures, as the firm pivots away from its clinical-stage cell therapy development.